GlassScriptPhysician profile
Naren S Shenoy
NPI 1275658569
$2,345.83
in general payments reported to CMS, 2019-2025
21 companies · $234 in 2025
The $234 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $197 · 2021: $459 · 2022: $250 · 2023: $303 · 2024: $570 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $442.42 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $337.05 | 2019-2025 | Bexsero, Penmenvy, Rotarix |
| Tris Pharma INC | $308.43 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $305.98 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $171.65 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $152.48 | 2019-2022 | |
| Cranial Technologies, INC | $109.55 | 2019-2024 | Doc Band |
| Adlon Therapeutics L.P. | $87.74 | 2020-2021 | |
| Sanofi Pasteur INC. | $74.91 | 2021-2025 | |
| Corium, LLC | $63.90 | 2021-2023 | Azstarys |
| Merck Sharp & Dohme LLC | $53.28 | 2019-2023 | Vaxneuvance, Gardasil 9, Rotateq |
| Aytu Biopharma, INC. | $48.21 | 2024-2025 | Karbinal |
| Collegium Pharmaceutical, INC. | $33.95 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $30.46 | 2019-2022 | |
| Neuraxis, INC. | $29.47 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $20.67 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $17.19 | 2019 | |
| Genentech USA, INC. | $16.27 | 2021 | |
| Sobi, INC | $16.23 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.84 | 2023 | Flumist Quadrivalent |
| Promius Pharma LLC | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naren Shenoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.